PLK1 and myeloid neoplasm: PLK1 (volasertib and onvansertib) inhibitors have completed clinical trials for patients with myeloid neoplasms (MDS and AML) with reasonable safety data, prompting us to establish the therapeutic efficacy of these agents in pCMML models22,42–44.